REFERENCES

• MillerAHMaleticVRaisonCL.Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression.Biol Psychiatry.20096573274119150053
   PubMed Web of Science ®Google Scholar
• HowrenMBLamkinDMSulsJ.Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.Psychosom Med.20097117118619188531
   PubMed Web of Science ®Google Scholar
• RaisonCLCapuronLMillerAH.Cytokines sing the blues: inflammation and the pathogenesis of depression.Trends Immunol.200627243116316783
   PubMed Web of Science ®Google Scholar
• HartBL.Biological basis of the behavior of sick animals.Neurosci Biobehav Rev.1988121231373050629
   PubMed Web of Science ®Google Scholar
• DantzerRO'ConnorJCFreundGGJohnsonRWKelleyKW.From inflammation to sickness and depression: when the immune system subjugates the brain.Nat Rev Neurosci.20089465618073775
   PubMed Web of Science ®Google Scholar
• DantzerR.Cytokine, sickness behavior, and depression.Immunol Allergy Clin North Am.20092924726419389580
   PubMed Web of Science ®Google Scholar
• FelgerJCAlagbeOHuFet al.Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression.Biol Psychiatry.2007621324133317678633
   PubMed Web of Science ®Google Scholar
• CapuronLFornwaltFBKnightBTHarveyPDNinanPTMillerAH.Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals?J Affect Disord.200911918118519269036
   PubMed Web of Science ®Google Scholar
• CapuronLMillerAH.Cytokines and psychopathology: lessons from interferon-alpha.Biol Psychiatry.20045681982415576057
   PubMed Web of Science ®Google Scholar
• CapuronLGumnickJFMusselmanDLet al.Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.Neuropsychopharmacology.20022664365211927189
   PubMed Web of Science ®Google Scholar
• MatriscianoFBonaccorsoSRicciardiAet al.Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine.J Psychiatr Res.20094324725418511076
   PubMed Web of Science ®Google Scholar
• BlutheRMLayeSMichaudBCombeCDantzerRParnetP.Role of interleukin-1beta and tumour necrosis factor-alpha in lipopolysaccharideinduced sickness behaviour: a study with interleukin-1 type I receptor-deficient mice.Eur J Neurosci.2000124447445611122355
   PubMed Web of Science ®Google Scholar
• DantzerR.Cytokine-induced sickness behavior: mechanisms and implications.Ann N Y Acad Sci.200193322223412000023
   PubMed Web of Science ®Google Scholar
• SheltonRCMillerAH.Eating ourselves to death (and despair): The contribution of adiposity and inflammation to depression.Progr Neurobiol.201091275299
   PubMed Web of Science ®Google Scholar
• DantzerRKelleyKW.Twenty years of research on cytokine-induced sickness behavior.Brain Behav Immun.20072115316017088043
   PubMed Web of Science ®Google Scholar
• HamiltonM.A rating scale for depression.J Neurol Neurosurg Psychiatry.196023566214399272
   PubMed Web of Science ®Google Scholar
• BentonTStaabJEvansDL.Medical co-morbidity in depressive disorders.Ann Clin Psychiatry.20071928930318058286
   PubMedGoogle Scholar
• HevenerALFebbraioMA.The 2009 Stock Conference Report: Inflammation, Obesity and Metabolic Disease.Obes Rev.20101163564420002885
   PubMed Web of Science ®Google Scholar
• MusselmanDLMillerAHPorterMRet al.Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings.Am J Psychiatry.20011581252125711481159
   PubMed Web of Science ®Google Scholar
• SoygurHPalaogluOAkarsuESet al.Interleukin-6 levels and HPA axis activation in breast cancer patients with major depressive disorder.Prog Neuropsychopharmacol Biol Psychiatry.2007311242124717587477
   PubMed Web of Science ®Google Scholar
• LutgendorfSKWeinribAZPenedoFet al.Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients.J Clin Oncol.2008264820482718779606
   PubMed Web of Science ®Google Scholar
• JehnCFKuehnhardtDBartholomaeAet al.Biomarkers of depression in cancer patients.Cancer.20061072723272917036362
   PubMed Web of Science ®Google Scholar
• MillerGEFreedlandKEDuntleySCarneyRM.Relation of depressive symptoms to C-reactive protein and pathogen burden (cytomegalovirus, herpes simplex virus, Epstein-Barr virus) in patients with earlier acute coronary syndromes.Am J Cardiol.20059531732115670537
   PubMed Web of Science ®Google Scholar
• JacobsonCMRosenfeldBPessinHBreitbartW.Depression and IL-6 blood plasma concentrations in advanced cancer patients.Psychosomatics.200849646618212178
   PubMed Web of Science ®Google Scholar
• DantzerRKelleyKW.Twenty years of research on cytokine-induced sickness behavior.Brain Behav Immun.20072115316017088043
   PubMed Web of Science ®Google Scholar
• BierhausAWolfJAndrassyMet al.A mechanism converting psychosocial stress into mononuclear cell activation.Proc Natl Acad Sci U S A.20031001920192512578963
   PubMed Web of Science ®Google Scholar
• PaceTWMletzkoTCAlagbeOet al.Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress.Am J Psychiatry.20061631630163316946190
   PubMed Web of Science ®Google Scholar
• ErmischARuhleHJLandgrafRHessJ.Blood-brain barrier and peptides.J Cereb Blood Flow Metab.198553503573897253
   PubMed Web of Science ®Google Scholar
• QuanNBanksWA.Brain-immune communication pathways. BrainBehav Immunity.200721727735
   PubMed Web of Science ®Google Scholar
• D'MelloCLeTSwainMG.Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factoralpha signaling during peripheral organ inflammation.J Neurosci.2009292089210219228962
   PubMed Web of Science ®Google Scholar
• DelgadoPLCharneyDSPriceLHAghajanianGKLandisHHeningerGR.Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan.Arch Gen Psychiatry.1990474114182184795
   PubMed Web of Science ®Google Scholar
• SchwarczRPellicciariR.Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities.J Pharmacol Exp Ther.200230311012235226
   PubMed Web of Science ®Google Scholar
• SchrocksnadelKWirleitnerBWinklerCFuchsD.Monitoring tryptophan metabolism in chronic immune activation.Clin Chim Acta.2006364829016139256
   PubMed Web of Science ®Google Scholar
• PopovAAbdullahZWickenhauserCet al.Indoleamine 2,3-dioxygenase-expressing dendritic cells form suppurative granulomas following Listeria monocytogenes infection.J Clin Invest.20061163160317017111046
   PubMed Web of Science ®Google Scholar
• TakikawaOTagawaYIwakuraYYoshidaRTruscottRJ.Interferongamma-dependent/independent expression of indoleamine 2,3-dioxygenase. Studies with interferon-gamma-knockout mice.Adv Exp Med Biol.199946755355710721099
   PubMed Web of Science ®Google Scholar
• O'ConnorJCLawsonMAAndreCet al.Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice.Mol Psychiatry.20091451152218195714
   PubMed Web of Science ®Google Scholar
• RassoulpourAWuHQFerreSSchwarczR.Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum.J Neurochem.20059376276515836634
   PubMed Web of Science ®Google Scholar
• AmoriLWuHQMarinozziMPellicciariRGuidettiPSchwarczR.Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum.Neuroscience.200915919620319138730
   PubMed Web of Science ®Google Scholar
• JangSJeongHSParkJSet al.Neuroprotective effects of (-)-epigallocatechin-3-gallate against quinolinic acid-induced excitotoxicity via pi3k pathway and NO inhibition.Brain Res.201011313C253320025854
   PubMedGoogle Scholar
• Owe-YoungRWebsterNLMukhtarMet al.Kynurenine pathway metabolism in human blood-brain-barrier cells: implications for immune tolerance and neurotoxicity.J Neurochem.20081051346135718221377
   PubMed Web of Science ®Google Scholar
• KwidzinskiEBechmannI.IDO expression in the brain: a double-edged sword.J Mol Med.2007851351135917594069
   PubMed Web of Science ®Google Scholar
• BrewBJHalmanMCatalanJet al.Factors in AIDS dementia complex trial design: results and lessons from the abacavir trial.PLoS Clin Trials.20072e1317401456
   PubMedGoogle Scholar
• GuilleminGJKerrSJBrewBJ.Involvement of quinolinic acid in AIDS dementia complex.Neurotox Res.2005710312315639803
   PubMed Web of Science ®Google Scholar
• ZadoriDKlivenyiPVamosEFulopFToldiJVecseiL.Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies.J Neural Transm.20091161403140919618107
   PubMed Web of Science ®Google Scholar
• VamosEPardutzAKlivenyiPToldiJVecseiL.The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection.J Neurol Sci.2009283212719268309
   PubMed Web of Science ®Google Scholar
• MosleyRLBennerEJKadiuIet al.Neuroinflammation, oxidative stress and the pathogenesis of parkinson's disease.Clin Neurosci Res.2006626128118060039
   PubMed Web of Science ®Google Scholar
• SasKRobotkaHToldiJVecseiL.Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders.J Neurol Sci.200725722123917462670
   PubMed Web of Science ®Google Scholar
• WichersMCKoekGHRobaeysGVerkerkRScharpeSMaesM.IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity.Mol Psychiatry.20051053854415494706
   PubMed Web of Science ®Google Scholar
• RaisonCLDantzerRKelleyKWet al.CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression.Mol Psychiatry. In press.
   Google Scholar
• BlakelyRDBersonHE.Molecular biology of serotonin receptors and transporters.Clin Neuropharmacol.199215(suppl 1 Pt A)351A352A
   PubMedGoogle Scholar
• ZhuCBCarneiroAMDostmannWRHewlettWABlakelyRD.p38 MAPK activation elevates serotonin transport activity via a trafficking-independent, protein phosphatase 2A-dependent processJ Biol Chem.2005280156491565815728187
   PubMed Web of Science ®Google Scholar
• TsaoCWLinYSChengJTet al.Interferon-alpha-induced serotonin uptake in Jurkat T cells via mitogen-activated protein kinase and transcriptional regulation of the serotonin transporter.J Psychopharmacol.20082275376018308792
   PubMed Web of Science ®Google Scholar
• SamuvelDJJayanthiLDBhatNRRamamoorthyS.A role for p38 mitogen-activated protein kinase in the regulation of the serotonin transporter: evidence for distinct cellular mechanisms involved in transporter surface expression.J Neurosci.2005252941 15634764
   PubMed Web of Science ®Google Scholar
• LotrichFEFerrellRERabinovitzMPollockBG.Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism.Biol Psychiatry.20096534434818801474
   PubMed Web of Science ®Google Scholar
• BullSJHuezo-DiazPBinderEBet al.Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment.Mol Psychiatry.2009141095110418458677
   PubMed Web of Science ®Google Scholar
• MusselmanDLLawsonDHGumnickJFet al.Paroxetine for the prevention of depression induced by high-dose interferon alfa.N Engl J Med.200134496196611274622
   PubMed Web of Science ®Google Scholar
• RaisonCLWoolwineBJDemetrashviliMFet al.Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C.Aliment Pharmacol Ther.2007251163117417451562
   PubMed Web of Science ®Google Scholar
• MorascoBJRifaiMALoftisJMIndestDWMolesJKHauserP.A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C.J Affect Disord.2007103839017292481
   PubMed Web of Science ®Google Scholar
• SchrammTMLawfordBRMacdonaldGACooksleyWG.Sertraline treatment of interferon-alfa-induced depressive disorder.Med J Aust.200017335936111062791
   PubMed Web of Science ®Google Scholar
• SammutSBethusIGoodallGMuscatR.Antidepressant reversal of interferon-alpha-induced anhedonia.Physiol Behav.20027576577212020742
   PubMed Web of Science ®Google Scholar
• LevensonJLFallonHJ.Fluoxetine treatment of depression caused by interferon-alpha.Am J Gastroenterol.1993887607618480744
   PubMed Web of Science ®Google Scholar
• KrausMRSchaferASchottkerKet al.Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, doubleblind, placebo-controlled study.Gut.20085753153618079286
   PubMed Web of Science ®Google Scholar
• GleasonOCFucciJCYatesWRPhilipsenMA.Preventing relapse of major depression during interferon-alpha therapy for hepatitis C--A pilot study.Dig Dis Sci.2007522557256317436092
   PubMed Web of Science ®Google Scholar
• SchaeferMSchwaigerMGarkischASet al.Prevention of interferonalpha associated depression in psychiatric risk patients with chronic hepatitis C.J Hepatol.20054279379815885349
   PubMed Web of Science ®Google Scholar
• LagunoMBlanchJMurillasJet al.Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis C.Antivir Ther.2004990590915651749
   PubMed Web of Science ®Google Scholar
• LoftisJMSochermanREHowellCDet al.Association of interferonalpha-induced depression and improved treatment response in patients with hepatitis C.Neurosci Lett.2004365879115245784
   PubMed Web of Science ®Google Scholar
• HauserPKhoslaJAuroraHet al.A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C.Mol Psychiatry.2002794294712399946
   PubMed Web of Science ®Google Scholar
• SalamoneJDCorreaM.Dopamine/adenosine interactions involved in effort-related aspects of food motivation.Appetite.20095342242519635514
   PubMed Web of Science ®Google Scholar
• DunlopBWNemeroffCB.The role of dopamine in the pathophysiology of depression.Arch Gen Psychiatry.20076432733717339521
   PubMed Web of Science ®Google Scholar
• CapuronLPagnoniGDemetrashviliMFet al.Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy.Neuropsychopharmacology.2007322384239217327884
   PubMed Web of Science ®Google Scholar
• JuenglingFDEbertDGutOet al.Prefrontal cortical hypometabolism during low-dose interferon alpha treatment.Psychopharmacology.200015238338911140330
   PubMed Web of Science ®Google Scholar
• SpetsierisPGMoellerJRDhawanVIshikawaTEidelbergD.Visualizing the evolution of abnormal metabolic networks in the brain using PET.Computerized Medical Imaging and Graphics.2005192953067641174
   PubMedGoogle Scholar
• FeiginAFukudaMDhawanVet al.Metabolic correlates of levodopa response in Parkinson's disease.Neurology.2001572083208811739830
   PubMed Web of Science ®Google Scholar
• FelgerJCAlagbeOHuFet al.Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression.Biol Psychiatry.2007621324133317678633
   PubMed Web of Science ®Google Scholar
• ShutoHKataokaYHorikawaTFujiharaNOishiR.Repeated interferon-[alpha] administration inhibits dopaminergic neural activity in the mouse brain.Brain Research.19977473483519046014
   PubMed Web of Science ®Google Scholar
• LouJSKearnsGBeniceTOkenBSextonGNuttJ.Levodopa improves physical fatigue in Parkinson's disease: a double-blind, placebocontrolled, crossover study.Mov Disord.2003181108111414534913
   PubMed Web of Science ®Google Scholar
• SchwartzALThompsonJAMasoodN.Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate.Oncol Nurs Forum.200229E85E9012183762
   PubMedGoogle Scholar
• BreitbartWRosenfeldBKaimMFunesti-EschJ.A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease.Arch Intern Med.200116141142011176767
   PubMedGoogle Scholar
• KitagamiTYamadaKMiuraHHashimotoRNabeshimaTOhtaT.Mechanism of systemically injected interferon-alpha impeding monoamine biosynthesis in rats: role of nitric oxide as a signal crossing the blood-brain barrier.Brain Research.200397810411412834904
   PubMed Web of Science ®Google Scholar
• MoronJAZakharovaIFerrerJVet al.Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity.J Neurosci.2003238480848813679416
   PubMed Web of Science ®Google Scholar
• BrustolimDRibeiro-dos-SantosRKastREAltschulerELSoaresMB.A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferongamma in mice.Int Immunopharmacol.2006690390716644475
   PubMed Web of Science ®Google Scholar
• Szuster-CiesielskaATustanowska-StachuraASlotwinskaMMarmurowska-MichalowskaHKandefer-SzerszenM.In vitro immunoregulatory effects of antidepressants in healthy volunteers.Pol J Pharmacol.20035535336214506314
   PubMedGoogle Scholar
• BengtssonBOZhuJThorellLHOlssonTLinkHWalinderJ.Effects of zimeldine and its metabolites, clomipramine, imipramine and maprotiline in experimental allergic neuritis in Lewis rats.J Neuroimmunol.1992391091221535634
   PubMed Web of Science ®Google Scholar
• SongCDinanTLeonardBE.Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls.J Affect Disord.1994302832887516941
   PubMed Web of Science ®Google Scholar
• ZhuJBengtssonBOMixEet al.Clomipramine and imipramine suppress clinical signs and T and B cell response to myelin proteins in experimental autoimmune neuritis in Lewis rats.J Autoimmun.1998113193279776709
   PubMed Web of Science ®Google Scholar
• ZhuJBengtssonBOMixEThorellLHOlssonTLinkH.Effect of monoamine reuptake inhibiting antidepressants on major histocompatibility complex expression on macrophages in normal rats and rats with experimental allergic neuritis (EAN).Immunopharmacology.1994272252448071062
   PubMedGoogle Scholar
• MaesMSongCLinAHet al.Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion.Neuropsychopharmacology.19992037037910088138
   PubMed Web of Science ®Google Scholar
• KuberaMLinAHKenisGBosmansEvan BDMaesM.AntiInflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio.J Clin Psychopharmacol.20012119920611270917
   PubMed Web of Science ®Google Scholar
• KuberaMKenisGBosmansEet al.Suppressive effect of TRH and imipramine on human interferon-gamma and interleukin-10 production in vitro.Pol J Pharmacol.20005248148611334244
   PubMedGoogle Scholar
• KuberaMMaesMHolanVBasta-KaimARomanAShaniJ.Prolonged desipramine treatment increases the production of interleukin10, an anti-inflammatory cytokine, in C57BL/6 mice subjected to the chronic mild stress model of depression.J Affect Disord.20016317117811246093
   PubMed Web of Science ®Google Scholar
• KuberaMSimbirtsevAMathisonRMaesM.Effects of repeated fluoxetine and citalopram administration on cytokine release in C57BL/6 mice.Psychiatry Res.200020;96255266
   Web of Science ®Google Scholar
• KuberaMKenisGBosmansEet al.Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: comparison between the acute state and after remission.Pol J Pharmacol.20005223724111055582
   PubMedGoogle Scholar
• MohrDCGoodkinDEIslarJHauserSLGenainCP.Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclerosis.Arch Neurol.2001581081108611448297
   PubMed Web of Science ®Google Scholar
• SeidelAAroltVHunstigerMRinkLBehnischAKirchnerH.Cytokine production and serum proteins in depression.Scand J Immunol.1995415345387539545
   PubMed Web of Science ®Google Scholar
• ObuchowiczEKowalskiJLabuzekKKrysiakRPendzichJHermanZS.Amitriptyline and nortriptyline inhibit interleukin-1 release by rat mixed glial and microglial cell cultures.Int J Neuropsychopharmacol.20069273515963243
   PubMed Web of Science ®Google Scholar
• LanquillonSKriegJCBening-Abu-ShachUVedderH.Cytokine production and treatment response in major depressive disorder.Neuropsychopharmacology.20002237037910700656
   PubMed Web of Science ®Google Scholar
• SluzewskaARybakowskiJKLaciakMMackiewiczASobieskaMWiktorowiczK.Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine.Ann N Y Acad Sci.19957624744767668562
   PubMed Web of Science ®Google Scholar
• BasterziADAydemirCKisaCet al.IL-6 levels decrease with SSRI treatment in patients with major depression.Hum Psychopharmacol.20052047347616158446
   PubMed Web of Science ®Google Scholar
• HestadKATonsethSStoenCDUelandTAukrustP.Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy.J ECT.20031918318814657769
   PubMed Web of Science ®Google Scholar
• MullerNSchwarzMJ.The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression.Mol Psychiatry.200712988100017457312
   PubMed Web of Science ®Google Scholar
• MyintAMLeonardBESteinbuschHWKimYK.Th1, Th2, and Th3 cytokine alterations in major depression.J Affect Disord.20058816717316126278
   PubMed Web of Science ®Google Scholar
• MyintAMSteinbuschHWGoegheganLLuchtmanDKimYKLeonardBE.Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomised rat model of depression.Neuroimmunomodulation.200714657117713352
   PubMed Web of Science ®Google Scholar
• GuoJYLiCYRuanYPet al.Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain.Eur J Pharmacol.2009612546019356723
   PubMed Web of Science ®Google Scholar
• KumariBKumarADhirA.Protective effect of non-selective and selective COX-2-inhibitors in acute immobilization stress-induced behavioral and biochemical alterations.Pharmacol Rep.20075969970718195459
   PubMed Web of Science ®Google Scholar
• Collantes-EstevezEFernandez-PerezC.Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain.Curr Med Res Opin.20031940241013678477
   PubMed Web of Science ®Google Scholar
• MendlewiczJKriwinPOswaldPSoueryDAlboniSBrunelloN.Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study.Int Clin Psychopharmacol.200621227231 16687994
   PubMed Web of Science ®Google Scholar
• MullerNSchwarzMJDehningSet al.The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a doubleblind, randomized, placebo controlled, add-on pilot study to reboxetine.Mol Psychiatry.20061168068416491133
   PubMed Web of Science ®Google Scholar
• TyringSGottliebAPappKet al.Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.Lancet.2006367293516399150
   PubMed Web of Science ®Google Scholar
• DaudenEGriffithsCOrtonneJPet al.Improvements in patientreported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study.J Eur Acad Dermatol Venereol.2009231374138219563497
   PubMed Web of Science ®Google Scholar
• KrishnanRCellaDLeonardiCet al.Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks.Br J Dermatol.20071571275127717916204
   PubMed Web of Science ®Google Scholar
• KekowJMootsRJEmeryPet al.Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial.Ann Rheum Dis.20106922222519293160
   PubMed Web of Science ®Google Scholar
• FeldmanSRGottliebABBalaMet al.Infliximab improves healthrelated quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis.Br J Dermatol.200815970471018627375
   PubMed Web of Science ®Google Scholar
• LichtensteinGRBalaMHanCDeWoodyKSchaibleT.Infliximab improves quality of life in patients with Crohn's disease.Inflamm Bowel Dis2002823724312131606
   PubMed Web of Science ®Google Scholar
• BornsteinSREhrhart-BornsteinMWongMLLicinioJ.Is the worldwide epidemic of obesity a communicable feature of globalization?Exp Clin Endocrinol Diabetes.2008116 (suppl 1)S30S3218777450
   PubMed Web of Science ®Google Scholar
• CumurcuBEOzyurtHEtikanIDemirSKarlidagRTotal antioxidant capacity and total oxidant status in patients with major depression: impact of antidepressant treatment.Psychiatry Clin Neurosci.20096363964519674383
   PubMed Web of Science ®Google Scholar
• WilbornCBeckhamJCampbellBet al.Obesity: prevalence, theories, medical consequences, management, and research directions.J Int Soc Sports Nutr.2005243118500955
   PubMed Web of Science ®Google Scholar
• WangYLobsteinT.Worldwide trends in childhood overweight and obesity.Int J Pediatr Obes.20061112517902211
   PubMed Web of Science ®Google Scholar
• MacPheeM.Global childhood obesity: how to curb an epidemic.J Pediatr Nurs.2008231418207042
   PubMedGoogle Scholar
• Ben-SeferEBen-NatanMEhrenfeldM.Childhood obesity: current literature, policy and implications for practice.Int Nurs Rev.20095616617319646165
   PubMed Web of Science ®Google Scholar
• BellentaniSMarinoM.Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD).Ann Hepatol.20098(suppl 1)S48S4S819381118
   PubMed Web of Science ®Google Scholar
• GoldenSHRobinsonKASaldanhaIAntonBLadensonPW.Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review.J Clin Endocrinol Metab.2009941853187819494161
   PubMed Web of Science ®Google Scholar
• HevenerALFebbraioMA.The 2009 Stock Conference Report: Inflammation, Obesity and Metabolic Disease.Obes Rev.20101163564420002885
   PubMed Web of Science ®Google Scholar
• ShoelsonSEHerreroLNaazA.Obesity, inflammation, and insulin resistance.Gastroenterology.20071322169218017498510
   PubMed Web of Science ®Google Scholar
• SutherlandJPMcKinleyBEckelRH.The metabolic syndrome and inflammation.Metab Syndr Relat Disord.200428210418370640
   PubMed Web of Science ®Google Scholar
• DandonaPAljadaAChaudhuriAMohantyPGargR.Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation.Circulation.20051111448145415781756
   PubMed Web of Science ®Google Scholar
• MillerGEFreedlandKECarneyRMStetlerCABanksWA.Pathways linking depression, adiposity, and inflammatory markers in healthy young adults.Brain Behav Immun.20031727628512831830
   PubMed Web of Science ®Google Scholar
• MathieuPPoirierPPibarotPLemieuxIDespresJP.Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease.Hypertension.20095357758419237685
   PubMed Web of Science ®Google Scholar
• CalabroPYehET.Intra-abdominal adiposity, inflammation, and cardiovascular risk: new insight into global cardiometabolic risk.Curr Hypertens Rep.200810323818367024
   PubMed Web of Science ®Google Scholar
• DespresJPArsenaultBJCoteMCartierALemieuxI.Abdominal obesity: the cholesterol of the 21st century?Can J Cardiol.200824 (suppl D)7D12D
   PubMedGoogle Scholar
• TilgHMoschenAR.Adipocytokines: mediators linking adipose tissue, inflammation and immunity.Nat Rev Immunol.2006677278316998510
   PubMed Web of Science ®Google Scholar
• TilgHMoschenAR.Inflammatory mechanisms in the regulation of insulin resistance.Mol Med.20081422223118235842
   PubMed Web of Science ®Google Scholar
• CarrMWRothSJLutherERoseSSSpringerTA.Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant.Proc Natl Acad Sci U S A.199491365236568170963
   PubMed Web of Science ®Google Scholar
• XuLLWarrenMKRoseWLGongWWangJM.Human recombinant monocyte chemotactic protein and other C-C chemokines bind and induce directional migration of dendritic cells in vitro.J Leukoc Biol.1996603653718830793
   PubMed Web of Science ®Google Scholar
• BrennanAMMantzorosCS.Drug insight: the role of leptin in human physiology and pathophysiology - emerging clinical applications.Nat Clin Pract End Met.20062318327
   PubMedGoogle Scholar
• ShapiroAMuWRoncalCChengKYJohnsonRJScarpacePJ.Fructose-induced leptin resistance exacerbates weight gain in response to subsequent high-fat feeding.Am J Physiol Regul Integr Comp Physiol.2008295R1370R137518703413
   PubMed Web of Science ®Google Scholar
• VasselliJR.Fructose-induced leptin resistance: discovery of an unsuspected form of the phenomenon and its significance. Focus on “Fructoseinduced leptin resistance exacerbates weight gain in response to subsequent high-fat feeding,” by Shapiro, et al.Am J Physiol Regul Integr Comp Physiol.2008295R1365R136918784330
   PubMed Web of Science ®Google Scholar
• LagoFDieguezCGomez-ReinoJGualilloO.Adipokines as emerging mediators of immune response and inflammation.Nat Clin Pract Rheumatol.2007371672418037931
   PubMedGoogle Scholar
• LagoFGomezRGomez-ReinoJJDieguezCGualilloO.Adipokines as novel modulators of lipid metabolism.Trends Biochem Sci.20093450051019729309
   PubMed Web of Science ®Google Scholar
• SilswalNSinghAKArunaBMukhopadhyaySGhoshSEhteshamNZ.Human resistin stimulates the pro-inflammatory cytokines TNF-[alpha] and IL-12 in macrophages by NF-[kappa]B-dependent pathway.Biochem Biophys Res Comm.20053341092110116039994
   PubMed Web of Science ®Google Scholar
• BaysHEGonzalez-CampoyJMBrayGAet al.Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity.Exp Rev Cardiovasc Ther.20086343368
   PubMedGoogle Scholar
• GustafsonB.Adipose tissue, inflammation and atherosclerosis.J Atheroscler Thromb.20101733234120124732
   PubMed Web of Science ®Google Scholar
• BreumLRasmussenMHHilstedJFernstromJD.Twenty-four-hour plasma tryptophan concentrations and ratios are below normal in obese subjects and are not normalized by substantial weight reduction.Am J Clin Nutr.2003771112111812716660
   PubMed Web of Science ®Google Scholar
• BrandacherGWinklerCAignerFet al.Bariatric surgery cannot prevent tryptophan depletion due to chronic immune activation in morbidly obese patients.Obes Surg.20061654154816687019
   PubMed Web of Science ®Google Scholar
• MurphyJMHortonNJBurkeJDJr.et al.Obesity and weight gain in relation to depression: findings from the Stirling County Study.Int J Obes (Lond).20093333534119139752
   PubMed Web of Science ®Google Scholar
• AtlantisEBakerM.Obesity effects on depression: systematic review of epidemiological studies.Int J Obes (Lond).20083288189118414420
   PubMed Web of Science ®Google Scholar
• VogelzangsNKritchevskySBBeekmanATet al.Obesity and onset of significant depressive symptoms: results from a prospective communitybased cohort study of older men and women.J Clin Psychiatry.20107139139920021992
   PubMed Web of Science ®Google Scholar
• VogelzangsNKritchevskySBBeekmanATet al.Depressive symptoms and change in abdominal obesity in older persons.Arch Gen Psychiatry.2008651386139319047525
   PubMed Web of Science ®Google Scholar
• VogelzangsNKritchevskySBBeekmanATFet al.Depressive symptoms and change in abdominal obesity in older persons.Arch Gen Psychiatry.2008651386139319047525
   PubMed Web of Science ®Google Scholar
• RivenesACHarveySBMykletunA.The relationship between abdominal fat, obesity, and common mental disorders: Results from the HUNT Study.J Psychosom Res.20096626927519302883
   PubMed Web of Science ®Google Scholar
• LuppinoFSde WitLMBouvyPFet al.Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies.Arch Gen Psychiatry.20106722022920194822
   PubMed Web of Science ®Google Scholar
• MillerGEStetlerCACarneyRMFreedlandKEBanksWA.Clinical depression and inflammatory risk markers for coronary heart disease.Am J Cardiol.2002901279128312480034
   PubMed Web of Science ®Google Scholar
• BaronRMKennyDA.The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations.J Pers Soc Psychol.198651117311823806354
   PubMed Web of Science ®Google Scholar
• MillerGEFreedlandKECarneyRMStetlerCABanksWA.Pathways linking depression, adiposity, and inflammatory markers in healthy young adults.Brain Behav Immun.20031727628512831830
   PubMed Web of Science ®Google Scholar
• ZimmermannMBAeberliI.Dietary determinants of subclinical inflammation, dyslipidemia and components of the metabolic syndrome in overweight children: a review.Int J Obes (Lond).200832(suppl 6)S11S1819079275
   PubMed Web of Science ®Google Scholar
• Rodriguez-LeyvaDDupasquierCMcCulloughRPierceGN.The cardiovascular effects of flaxseed and its omega-3 fatty acid, alpha-linolenic acid.Can J Cardiol.20102648949621076723
   PubMed Web of Science ®Google Scholar
• Bushkin-BedientSCarpenterDO.Benefits versus risks associated with consumption of fish and other seafood.Rev Environ Health.20102516119121038755
   PubMedGoogle Scholar
• ChangCLSeoTDuCBAcciliDDeckelbaumRJ.n-3 Fatty acids decrease arterial low-density lipoprotein cholesterol delivery and lipoprotein lipase levels in insulin-resistant mice.Arterioscler Thromb Vasc Biol.2010302510251720930167
   PubMed Web of Science ®Google Scholar
• HassanKSHassanSKHijaziEGKhazimKO.Effects of omega-3 on lipid profile and inflammation markers in peritoneal dialysis patients.Ren Fail.2010321031103520863205
   PubMed Web of Science ®Google Scholar
• DefilippisAPBlahaMJJacobsonTA.Omega-3 fatty acids for cardiovascular disease prevention.Curr Treat Options Cardiovasc Med.20101236538020842560
   PubMedGoogle Scholar
• HarrisWS.The omega-3 index: clinical utility for therapeutic intervention.Curr Cardiol Rep.20101250350820809235
   PubMedGoogle Scholar
• MazzaMPomponiMJaniriLBriaPMazzaS.Omega-3 fatty acids and antioxidants in neurological and psychiatric diseases: an overview.Prog Neuropsychopharmacol Biol Psychiatry.200731122616938373
   PubMed Web of Science ®Google Scholar
• JuturuV.Omega-3 fatty acids and the cardiometabolic syndrome.J Cardiometab Syndr.2008324425319040594
   PubMedGoogle Scholar
• RuxtonCHReedSCSimpsonMJMillingtonKJ.The health benefits of omega-3 polyunsaturated fatty acids: a review of the evidence.J Hum Nutr Diet.20041744945915357699
   PubMed Web of Science ®Google Scholar
• KraguljacNVMontoriVMPavuluriMChaiHSWilsonBSUnalSS.Efficacy of omega-3 Fatty acids in mood disorders - a systematic review and metaanalysis.Psychopharmacol Bull.200942395419752840
   PubMed Web of Science ®Google Scholar
• AstorgPCouthouisABertraisSet al.Association of fish and longchain n-3 polyunsaturated fatty acid intakes with the occurrence of depressive episodes in middle-aged French men and women.Prostaglandins, Leukotrienes Essential Fatty Acids.200878 171182
   PubMed Web of Science ®Google Scholar
• MalhotraAKGoldmanDMazzantiCCliftonABreierAPickarD.A functional serotonin transporter (5-HTT) polymorphism is associated with psychosis in neuroleptic-free schizophrenics.Molecular Psychiatry.199833283329702741
   PubMed Web of Science ®Google Scholar
• WillettWCSacksFTrichopoulouAet al.Mediterranean diet pyramid: a cultural model for healthy eating.Am J Clin Nutr.1995611402S1406S7754995
   PubMed Web of Science ®Google Scholar
• TortosaABes-RastrolloMSanchez-VillegasAet al.Mediterranean diet inversely associated with the incidence of metabolic syndrome.Diabetes Care.2007302957295917712023
   PubMed Web of Science ®Google Scholar
• Sanchez-VillegasADelgado-RodriguezMAlonsoAet al.Association of the Mediterranean dietary pattern with the incidence of depression: the Seguimiento Universidad de Navarra/University of Navarra Follow-up (SUN) Cohort.Arch Gen Psychiatry.2009661090109819805699
   PubMed Web of Science ®Google Scholar
• DaiJMillerAHBremnerJDet al.Adherence to the Mediterranean diet is inversely associated with circulating interleukin-6 among middleaged men: a twin study.Circulation.200811716917518086924
   PubMed Web of Science ®Google Scholar
• MarriottBPColeNLeeE.National estimates of dietary fructose intake increased from. 1977 to 2004 in the United States.J Nutr.20091391228S1235S19403716
   PubMed Web of Science ®Google Scholar
• JohnsonRJSegalMSSautinYet al.Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease.Am J Clin Nutr.20078689990617921363
   PubMed Web of Science ®Google Scholar
• StanhopeKLHavelPJ.Endocrine and metabolic effects of consuming beverages sweetened with fructose, glucose, sucrose, or high-fructose corn syrup.Am J Clin Nutr.2008881733S1737S19064538
   PubMed Web of Science ®Google Scholar
• SchaeferEJGleasonJADansingerML.Dietary fructose and glucose differentially affect lipid and glucose homeostasis.J Nutr.20091391257S1262S19403705
   PubMed Web of Science ®Google Scholar
• StanhopeKLHavelPJ.Fructose consumption: considerations for future research on its effects on adipose distribution, lipid metabolism, and insulin sensitivity in humans.J Nutr.20091391236S1241S19403712
   PubMed Web of Science ®Google Scholar
• DolanLCPotterSMBurdockGA.Evidence-based review on the effect of normal dietary consumption of fructose on development of hyperlipidemia and obesity in healthy, normal weight individuals.Crit Rev Food Sci Nutr.201050538420047139
   PubMed Web of Science ®Google Scholar
• TappyLLeKA.Metabolic effects of fructose and the worldwide increase in obesity.Physiol Rev.201090234620086073
   PubMed Web of Science ®Google Scholar
• WhiteJS.Misconceptions about high-fructose corn syrup: is it uniquely responsible for obesity, reactive dicarbonyl compounds, and advanced glycation endproducts?J Nutr.20091391219S1227S19386820
   PubMed Web of Science ®Google Scholar
• BocarslyMEPowellESAvenaNMHoebelBG.High-fructose corn syrup causes characteristics of obesity in rats: Increased body weight, body fat and triglyceride levels.Pharmacol Biochem Behav.20109710110620219526
   PubMed Web of Science ®Google Scholar
• TappyLLeKA.Metabolic effects of fructose and the worldwide increase in obesity.Physiol Rev.201090234620086073
   PubMed Web of Science ®Google Scholar
• FiglewiczDPIoannouGBennettJJKittlesonSSavardCRothCL.Effect of moderate intake of sweeteners on metabolic health in the rat.Physiol Behav.20099861862419815021
   PubMed Web of Science ®Google Scholar
• AngelopoulosTJLowndesJZukleyLet al.The effect of high-fructose corn syrup consumption on triglycerides and uric acid.J Nutr.20091391242S1245S19403709
   PubMed Web of Science ®Google Scholar
• SchaeferEJGleasonJADansingerML.Dietary fructose and glucose differentially affect lipid and glucose homeostasis.J Nutr.20091391257S1262S19403705
   PubMed Web of Science ®Google Scholar
• BascianoHFedericoLAdeliK.Fructose, insulin resistance, and metabolic dyslipidemia.Nutr Metab (Lond).20052515723702
   PubMedGoogle Scholar
• MoranTH.Fructose and satiety.J Nutr.20091391253S1256S19403706
   PubMed Web of Science ®Google Scholar
• StanhopeKLHavelPJ.Fructose consumption: potential mechanisms for its effects to increase visceral adiposity and induce dyslipidemia and insulin resistance.Curr Opin Lipidol.200819162418196982
   PubMed Web of Science ®Google Scholar
• PeetM.Eicosapentaenoic acid in the treatment of schizophrenia and depression: rationale and preliminary double-blind clinical trial results.Prostaglandins Leukot Essent Fatty Acids.20036947748514623502
   PubMed Web of Science ®Google Scholar
• FrangouSLewisMMcCroneP.Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study.Br J Psychiatry .2006188465016388069
   PubMed Web of Science ®Google Scholar
• MischoulonDPapakostasGIDordingCMet al.A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder.J Clin Psychiatry.2010701636164419709502
   PubMed Web of Science ®Google Scholar
• NemetsBStahlZBelmakerRH.Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder.Am J Psychiatry.200215947747911870016
   PubMed Web of Science ®Google Scholar
• SuKP.Mind-body interface: the role of n-3 fatty acids in psychoneuroimmunology, somatic presentation, and medical illness comorbidity of depression.Asia Pac J Clin Nutr.200817 (suppl 1)15115718296325
   PubMed Web of Science ®Google Scholar
• TamCSClementKBaurLATordjmanJ.Obesity and low-grade inflammation: a paediatric perspective.Obes Rev.20101111812619845868
   PubMed Web of Science ®Google Scholar
• WarnbergJMarcosA.Low-grade inflammation and the metabolic syndrome in children and adolescents.Curr Opin Lipidol.200819111518196981
   PubMed Web of Science ®Google Scholar
• MollestonJPWhiteFTeckmanJFitzgeraldJF.Obese children with steatohepatitis can develop cirrhosis in childhood.Am J Gastroenterol.2002972460246212358273
   PubMed Web of Science ®Google Scholar
• RobertsEA.Nonalcoholic steatohepatitis in children.Curr Gastroenterol Rep.2003525325912734049
   PubMedGoogle Scholar
• NandaK.Non-alcoholic steatohepatitis in children.Pediatr Transplant.2004861361815598336
   PubMed Web of Science ®Google Scholar
• SemizSRotaSOzdemirOOzdemirAKaptanogluB.Are C-reactive protein and homocysteine cardiovascular risk factors in obese children and adolescents?Pediatr Int.20085041942319143962
   PubMed Web of Science ®Google Scholar
• AlisiAMancoMPaneraNNobiliV.Association between type two diabetes and non-alcoholic fatty liver disease in youth.Ann Hepatol.20098 (suppl 1)S44S5019381124
   PubMed Web of Science ®Google Scholar
• ChiarelliFMarcovecchioML.Insulin resistance and obesity in childhood.Eur J Endocrinol.2008159 (suppl 1)S67S7418805916
   PubMed Web of Science ®Google Scholar
• EyzaguirreFMericqV.Insulin resistance markers in children.Horm Res.200971657419129710
   PubMedGoogle Scholar
• McElroySLKotwalRMalhotraSNelsonEBKeckPENemeroffCB.Are mood disorders and obesity related? A review for the mental health professional.J Clin Psychiatry.20046563465115163249
   PubMed Web of Science ®Google Scholar
• GoodwinRDSouranderADuarteCSet al.Do mental health problems in childhood predict chronic physical conditions among males in early adulthood? Evidence from a community-based prospective study.Psychol Med.20093930131118507873
   PubMed Web of Science ®Google Scholar
• HaslerGPineDSGammaAet al.The associations between psychopathology and being overweight: a. 20-year prospective study.Psychol Med.2004341047105715554575
   PubMed Web of Science ®Google Scholar
• Pulkki-RabackLElovainioMKivimakiMet al.Depressive symptoms and the metabolic syndrome in childhood and adulthood: a prospective cohort study.Health Psychol.20092810811619210024
   PubMed Web of Science ®Google Scholar
• ReevesGMPostolacheTTSnitkerS.Childhood obesity and depression: connection between these growing problems in growing children.Int J Child Health Hum Dev.2008110311418941545
   PubMedGoogle Scholar
• OkifujiADonaldsonGWBarckLFinePG.Relationship between fibromyalgia and obesity in pain, function, mood, and sleep.J Pain.2010111329133720542742
   PubMed Web of Science ®Google Scholar
• ArranzLICanelaMARafecasM.Fibromyalgia and nutrition, what do we know?Rheumatol Int.2010301417142720358204
   PubMed Web of Science ®Google Scholar
• WrightLJSchurENoonanCAhumadaSBuchwaldDAfariN.Chronic pain, overweight, and obesity: findings from a community-based twin registry.J Pain.20101162863520338816
   PubMed Web of Science ®Google Scholar
• MorkPJVasseljenONilsenTI.Association between physical exercise, body mass index, and risk of fibromyalgia: longitudinal data from the Norwegian Nord-Trondelag Health Study.Arthritis Care Res (Hoboken ).20106261161720191480
   PubMed Web of Science ®Google Scholar
• OliverJESilmanAJ.What epidemiology has told us about risk factors and aetiopathogenesis in rheumatic diseases.Arthritis Res Ther.20091122319490599
   PubMed Web of Science ®Google Scholar
• OkifujiABradshawDHOlsonC.Evaluating obesity in fibromyalgia: neuroendocrine biomarkers, symptoms, and functions.Clin Rheumatol.20092847547819172342
   PubMed Web of Science ®Google Scholar
• TrockD.Tired, achy, and overweight, the inflammatory nature of obesity.J Clin Rheumatol.2009155019131768
   PubMed Web of Science ®Google Scholar
• NeumannLLernerEGlazerYBolotinASheferABuskilaD.A crosssectional study of the relationship between body mass index and clinical characteristics, tenderness measures, quality of life, and physical functioning in fibromyalgia patients.Clin Rheumatol.2008271543154718622575
   PubMed Web of Science ®Google Scholar
• ZhangZCherryholmesGMaoAet al.High plasma levels of MCP-1 and eotaxin provide evidence for an immunological basis of fibromyalgia.Exp Biol Med (Maywood).20082331171118018535166
   PubMed Web of Science ®Google Scholar
• BennettRMJonesJTurkDCRussellIJMatallanaL.An internet survey of 2,596 people with fibromyalgia.BMC Musculoskelet Disord.200782717349056
   PubMed Web of Science ®Google Scholar
• JonesKDAdamsDWinters-StoneKBurckhardtCS.A comprehensive review of 46 exercise treatment studies in fibromyalgia (1988-2005).Health Qual Life Outcomes.200646716999856
   PubMed Web of Science ®Google Scholar
• KatzPGregorichSYazdanyJet al.Obesity and its measurement in a community-based sample of women with systemic lupus erythematosus.Arthritis Care Res (Hoboken).2010
   Web of Science ®Google Scholar
• HahnBHLourenccoEVMcMahonMet al.Pro-inflammatory highdensity lipoproteins and atherosclerosis are induced in lupus-prone mice by a high-fat diet and leptin.Lupus.20101991391720410156
   PubMed Web of Science ®Google Scholar
• ParasMLMuradMHChenLPet al.Sexual abuse and lifetime diagnosis of somatic disorders: a systematic review and meta-analysis.JAMA.200930255056119654389
   PubMed Web of Science ®Google Scholar
• PapakostasGIPetersenTIosifescuDVet al.Obesity among outpatients with major depressive disorder.Int J Neuropsychopharmacol.20058596315361263
   PubMed Web of Science ®Google Scholar
• OskooilarNWilcoxCSTongMLGroszDE.Body mass index and response to antidepressants in depressed research subjects.J Clin Psychiatry.2009701609161020031110
   PubMed Web of Science ®Google Scholar
• MarkowitzSFriedmanFAArentSM.Understanding the relation between obesity and depression: causal mechanisms and implications for treatment.Clin Psychol Sci Pract.200815120
   Web of Science ®Google Scholar
• CiceroAFDerosaGBoveMDiGVGaddiAVBorghiC.Effect of a sequential training programme on inflammatory, prothrombotic and vascular remodelling biomarkers in hypertensive overweight patients with or without metabolic syndrome.Eur J Cardiovasc Prev Rehabil.20091669870419741540
   PubMedGoogle Scholar
• ForsytheLKWallaceJMLivingstoneMB.Obesity and inflammation: the effects of weight loss. 200821117133
   Google Scholar
• KelishadiRHashemiMMohammadifardNAsgarySKhavarianN.Association of changes in oxidative and proinflammatory states with changes in vascular function after a lifestyle modification trial among obese children.Clin Chem.20085414715317998270
   PubMed Web of Science ®Google Scholar